moxifloxacin has been researched along with lansoprazole in 11 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (lansoprazole) | Trials (lansoprazole) | Recent Studies (post-2010) (lansoprazole) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 2,281 | 803 | 600 |
| Protein | Taxonomy | moxifloxacin (IC50) | lansoprazole (IC50) |
|---|---|---|---|
| phosphoethanolamine/phosphocholine phosphatase isoform 1 | Homo sapiens (human) | 0.434 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 0.995 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 5.3148 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 0.3367 | |
| WD repeat-containing protein 5 | Homo sapiens (human) | 5.9 | |
| Histone-lysine N-methyltransferase 2A | Homo sapiens (human) | 5.9 | |
| Indoleamine 2,3-dioxygenase 2 | Mus musculus (house mouse) | 8.2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bartolozzi, F; Cammarota, G; Candelli, M; Cremonini, F; Di Caro, S; Gasbarrini, A; Lupascu, A; Nista, EC; Ojetti, V; Zocco, MA | 1 |
| Akbal, E; Koçak, E; Köklü, S; Taş, A | 1 |
| Ergül, B; Filik, L; Koçak, E; Köklü, S; Taş, A | 1 |
| Akdoğan, RA; Bedir, R; Copur, A; Rakici, H; Yilmaz, A | 1 |
| Akdogan, RA; Ayaz, T; Bedir, R; Rakici, H | 1 |
1 review(s) available for moxifloxacin and lansoprazole
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
5 trial(s) available for moxifloxacin and lansoprazole
| Article | Year |
|---|---|
Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anti-Bacterial Agents; Aza Compounds; Clarithromycin; Drug Combinations; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Moxifloxacin; Omeprazole; Patient Compliance; Quinolines; Treatment Outcome | 2002 |
Moxifloxacin-tetracycline-lansoprazole triple therapy for first-line treatment of Helicobacter pylori infection: a prospective study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Aza Compounds; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Moxifloxacin; Prospective Studies; Quinolines; Tetracycline; Treatment Outcome; Young Adult | 2011 |
Bismuth, moxifloxacin, tetracycline, lansoprazole quadruple first line therapy for eradication of H. pylori: A prospective study.
Topics: Adult; Aged; Antacids; Anti-Bacterial Agents; Aza Compounds; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Medication Adherence; Middle Aged; Moxifloxacin; Organometallic Compounds; Prospective Studies; Proton Pump Inhibitors; Quinolines; Tetracycline; Young Adult | 2013 |
Comparison of standard triple therapy, sequential therapy and moxifloxacin-based triple therapy for Helicobacter pylori infection: Patients' compliance and bacterial eradication rates.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Medication Adherence; Metronidazole; Middle Aged; Moxifloxacin; Proton Pump Inhibitors; Treatment Outcome; Young Adult | 2014 |
Comparison of levofloxacin- and moxifloxacin-based triple therapies with standard treatment in eradication of Helicobacter pylori as first-line therapy.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Levofloxacin; Male; Middle Aged; Moxifloxacin; Proton Pump Inhibitors; Treatment Outcome; Young Adult | 2014 |
5 other study(ies) available for moxifloxacin and lansoprazole
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |